Drug intelligence / Profile preview

Lactiplantibacillus plantarum PBS067

Development stage
Preclinical
Lead developer
SynBalance
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral, Vaginal, Topical
01

Overview

Lactiplantibacillus plantarum PBS067 is a specific probiotic strain developed by SynBalance Srl. It has been investigated for its beneficial effects on oral, urogenital, skin, and gastrointestinal health. Research indicates it has antimicrobial and anti-adhesive properties against various pathogens, including those involved in dental caries and periodontal disease (Streptococcus mutans and Aggregatibacter actinomycetemcomitans) and urogenital infections (Candida glabrata, Neisseria gonorrheae, Trichomonas vaginalis, and Escherichia coli). [1, 2] Its mechanism of action involves competing with pathogens, producing antimicrobial substances like organic acids, strengthening epithelial barriers, and modulating the immune system. [2, 4, 5] For instance, when studied as part of an oral combination supplement in post-menopausal women, it helped restore a healthy vaginal microbiota, reduce levels of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α, and improve symptoms of vaginal atrophy. [1] It is also utilized in cosmetic products for its purported ability to balance the skin microbiome and reinforce the skin's natural barrier. [2]

Other names
Lactobacillus plantarum PBS067

Beyond the preview

Go deeper on Lactiplantibacillus plantarum PBS067.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactiplantibacillus plantarum PBS067.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call